Eric D Collins
Overview
Explore the profile of Eric D Collins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Foltin R, Ward A, Collins E, Haney M, Hart C, Fischman M
Exp Clin Psychopharmacol
. 2003 May;
11(2):123-30.
PMID: 12755456
The effects of maintenance on venlafaxine, which blocks both norepinephrine and serotonin reuptake, on the response to smoked cocaine (0, 12, 25, or 50 mg) in 7 opioid-free and 7...
12.
13.
Foltin R, Ward A, Haney M, Hart C, Collins E
Drug Alcohol Depend
. 2003 May;
70(2):149-57.
PMID: 12732408
This study examined the effects of escalating doses of smoked cocaine in non-treatment-seeking cocaine users. Cocaine sessions were conducted twice per day for 3 consecutive days. During each session, one...
14.
Comer S, Collins E
J Pharmacol Exp Ther
. 2002 Oct;
303(2):695-703.
PMID: 12388653
Buprenorphine is a partial mu-opioid agonist and kappa-opioid antagonist currently under development as a maintenance medication for heroin dependence. Because of concerns about illicit diversion of buprenorphine, a combination tablet...
15.
Comer S, Collins E, Fischman M
J Pharmacol Exp Ther
. 2002 Mar;
301(1):266-76.
PMID: 11907183
Several sources indicate that intravenously administered buprenorphine may have significant abuse liability in humans. The present study evaluated the reinforcing effects of intravenously administered buprenorphine (0, 2, and 8 mg)...
16.
Comer S, Collins E, Kleber H, Nuwayser E, Kerrigan J, Fischman M
Psychopharmacology (Berl)
. 2002 Feb;
159(4):351-60.
PMID: 11823887
Rationale: Naltrexone, an opioid antagonist, is currently approved as a treatment for heroin dependence. However, naltrexone is generally not well accepted by patients, and medication non-compliance is a difficult obstacle...